Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

about

British Journal of Biomedical Science in 2016. What have we learned?Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study.

P2860

Q39138486-4E61F0FD-9D26-4E46-AD7F-EADECDC3331C Q51737332-6FBD3B02-5D17-42FA-91F4-F708F19349F0

P2860

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

Item

http://www.wikidata.org/entity/Q53063628

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@en

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@nl

type

Item

label

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@en

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@nl

prefLabel

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@en

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@nl

P1476

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

@en

P2093

Guang Qian

http://www.w3.org/2001/XMLSchema#string

Guangchun Sun

http://www.w3.org/2001/XMLSchema#string

Qingqing Qian

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Rivaroxaban: a new oral factor Xa inhibitor.

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.

Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.

Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.

Diagnosis and treatment of inherited factor X deficiency.

Determining the effect of freezing on coagulation testing: comparison of results between fresh and once frozen-thawed plasma.

Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

P304

134-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09674845.2016.1195151

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27400196

http://www.w3.org/2001/XMLSchema#string

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

about

P2860

P2860

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698